Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Br. J. Dermatol.

Title: The British journal of dermatology

ISSN (Electronic): 1365-2133

ISSN (Print): 0007-0963

Publication date (Electronic): Oct 2015

Volume: 173

Issue: 4

Affiliations

[1 ] Probity Medical Research and K Papp Clinical Research Inc., 135 Union Street East, Waterloo, ON, N2J 1C4, Canada.

[2 ] Baylor Research Institute, Dallas, TX, U.S.A.

[3 ] Gunma University Hospital, Maebashi, Gunma, Japan.

[4 ] University of Alabama, Tuscaloosa, AL, U.S.A.

[5 ] Wake Forest Baptist Health, Winston-Salem, NC, U.S.A.

[6 ] Tufts Medical Center, Boston, MA, U.S.A.

[7 ] Dalhousie University, Halifax, NS, Canada.

[8 ] University of Münster, Münster, Germany.

[9 ] University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

[10 ] Pfizer Inc., Groton, CT, U.S.A.

Article

DOI: 10.1111/bjd.14018

PubMed ID: 26149717

SO-VID: 3bd42e41-dcee-4261-8f15-09f31ed74b12

History

Data availability:

Comments

Comment on this article

scite_

Cited by 107

See all cited by